POLE and glioblastoma: A recent randomized phase II study failed to demonstrate the efficacy of either pembrolizumab alone or pembrolizumab plus bevacizumab in recurrent glioblastoma.7 However, TMB and mutational profiles including POLE mutation were not reported in this study.